46.76
price up icon0.03%   0.0008
 
loading
Precedente Chiudi:
$46.76
Aprire:
$46.35
Volume 24 ore:
2.71M
Relative Volume:
0.67
Capitalizzazione di mercato:
$112.55B
Reddito:
$49.41B
Utile/perdita netta:
$5.59B
Rapporto P/E:
19.59
EPS:
2.3875
Flusso di cassa netto:
$8.32B
1 W Prestazione:
-1.73%
1M Prestazione:
+7.28%
6M Prestazione:
-4.15%
1 anno Prestazione:
-9.17%
Intervallo 1D:
Value
$46.06
$46.90
Intervallo di 1 settimana:
Value
$46.06
$47.59
Portata 52W:
Value
$43.32
$55.73

Sanofi Adr Stock (SNY) Company Profile

Name
Nome
Sanofi Adr
Name
Telefono
-
Name
Indirizzo
-
Name
Dipendente
74,846
Name
Cinguettio
@sanofi
Name
Prossima data di guadagno
2026-04-23
Name
Ultimi documenti SEC
Name
SNY's Discussions on Twitter

Compare SNY vs LLY, JNJ, ABBV, AZN, MRK

Azioni Prezzo Cap. di mercato Reddito Reddito netto Flusso di cassa EPS
SNY icon
SNY
Sanofi Adr
46.77 112.51B 49.41B 5.59B 8.32B 2.3875
LLY icon
LLY
Lilly Eli Co
928.48 839.28B 65.18B 20.64B 5.96B 22.59
JNJ icon
JNJ
Johnson Johnson
236.85 574.36B 94.19B 26.80B 19.70B 11.05
ABBV icon
ABBV
Abbvie Inc
204.54 367.80B 61.16B 4.19B 17.82B 2.3614
AZN icon
AZN
Astrazeneca Plc
202.47 316.42B 58.80B 10.24B 8.98B 3.2788
MRK icon
MRK
Merck Co Inc
119.79 299.89B 64.93B 18.26B 12.36B 7.2751

Sanofi Adr Stock (SNY) Upgrades & Downgrades

Data Azione Analista Modifica della valutazione
2026-02-12 Downgrade BofA Securities Buy → Neutral
2026-01-27 Iniziato Citigroup Neutral
2026-01-16 Downgrade UBS Buy → Neutral
2026-01-06 Downgrade Barclays Overweight → Equal Weight
2025-12-09 Downgrade Guggenheim Buy → Neutral
2025-12-08 Downgrade JP Morgan Overweight → Neutral
2025-09-08 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2025-09-02 Aggiornamento Deutsche Bank Hold → Buy
2025-08-08 Aggiornamento JP Morgan Neutral → Overweight
2025-04-15 Iniziato Exane BNP Paribas Outperform
2025-03-21 Iniziato Goldman Neutral
2025-01-30 Aggiornamento Deutsche Bank Sell → Hold
2024-07-26 Reiterato Argus Buy
2024-01-23 Iniziato Morgan Stanley Equal-Weight
2024-01-16 Ripresa UBS Buy
2023-12-05 Downgrade JP Morgan Overweight → Neutral
2023-10-30 Downgrade Stifel Buy → Hold
2023-09-06 Aggiornamento Berenberg Hold → Buy
2023-07-14 Iniziato HSBC Securities Buy
2023-04-28 Downgrade Deutsche Bank Hold → Sell
2023-03-27 Aggiornamento Barclays Equal Weight → Overweight
2022-12-13 Ripresa Morgan Stanley Overweight
2022-08-12 Aggiornamento Deutsche Bank Sell → Hold
2022-08-09 Downgrade UBS Buy → Neutral
2022-05-23 Iniziato SVB Leerink Outperform
2021-09-27 Aggiornamento SVB Leerink Mkt Perform → Outperform
2021-01-15 Iniziato Deutsche Bank Sell
2020-09-29 Iniziato Berenberg Hold
2020-03-17 Aggiornamento Barclays Underweight → Equal Weight
2020-03-11 Aggiornamento Goldman Neutral → Buy
2020-02-11 Iniziato SVB Leerink Mkt Perform
2020-01-06 Aggiornamento JP Morgan Neutral → Overweight
2019-09-23 Aggiornamento Guggenheim Neutral → Buy
2019-09-20 Aggiornamento Morgan Stanley Equal-Weight → Overweight
2019-09-03 Iniziato Bernstein Outperform
2019-08-14 Aggiornamento UBS Neutral → Buy
2018-12-11 Aggiornamento Jefferies Hold → Buy
2018-11-01 Aggiornamento Barclays Underweight → Equal Weight
2018-10-09 Iniziato Guggenheim Neutral
2018-09-10 Aggiornamento BofA/Merrill Neutral → Buy
2018-08-10 Aggiornamento Citigroup Neutral → Buy
2018-03-23 Aggiornamento Liberum Hold → Buy
2018-01-23 Downgrade Barclays Equal Weight → Underweight
2017-12-06 Downgrade BofA/Merrill Buy → Neutral
2017-12-01 Downgrade Morgan Stanley Overweight → Underweight
2017-11-15 Aggiornamento Barclays Underweight → Equal Weight
2017-08-30 Aggiornamento HSBC Securities Reduce → Hold
Mostra tutto

Sanofi Adr Borsa (SNY) Ultime notizie

pulisher
01:00 AM

Eosinophilic Esophagitis Market in the US to Grow at 13.2% CAGR During the Forecast Period (2026–2036) Owing to the Emergence of Drug Classes Such as TSLP Inhibitors, Glucocorticoid Receptor Agonists, and Immunomodulators | DelveInsight - GlobeNewswire Inc.

01:00 AM
pulisher
Apr 10, 2026

SNY Earnings History & Surprises | EPS & Revenue Results | SANOFI-ADR (NASDAQ:SNY) - ChartMill

Apr 10, 2026
pulisher
Apr 07, 2026

Sanofi (SNY) Stock Price, News, Quote & History - Yahoo! Finance Canada

Apr 07, 2026
pulisher
Apr 02, 2026

SNY Stock Price, Quote & Chart | SANOFI-ADR (NASDAQ:SNY) - ChartMill

Apr 02, 2026
pulisher
Mar 31, 2026

Morgan Stanley lowers Sanofi stock price target on FX update - Investing.com UK

Mar 31, 2026
pulisher
Mar 31, 2026

Morgan Stanley lowers Sanofi stock price target on FX update By Investing.com - Investing.com Canada

Mar 31, 2026
pulisher
Mar 27, 2026

AstraZeneca Strengthens Position In COPD Race With Successful Trials - Sahm

Mar 27, 2026
pulisher
Mar 25, 2026

Sanofi ADR (NASDAQ:SNY) Presents a Classic Value Investment Case - ChartMill

Mar 25, 2026
pulisher
Mar 24, 2026

Sanofi S.A. stock faces pressure amid dividend payout and sector headwinds on Euronext Paris - AD HOC NEWS

Mar 24, 2026
pulisher
Mar 21, 2026

Medicare Chief Chris Klomp Optimistic On CDC Director Search As Vaccine Fight Roils Agency— 'We Will Select...' - Sahm

Mar 21, 2026
pulisher
Mar 17, 2026

Federal Judge Flags Legal Flaws In RFK Jr.'s Vaccine Overhaul - Sahm

Mar 17, 2026
pulisher
Mar 11, 2026

Sanofi (NASDAQ:SNY) Emerges as a Top Dividend Stock from Methodical Screening - ChartMill

Mar 11, 2026
pulisher
Mar 10, 2026

Dupixent Leads the Charge for Sanofi's Strong Portfolio in Immunology, Vaccines, and Rare Diseases - Morningstar

Mar 10, 2026
pulisher
Mar 02, 2026

MRNA Stock Gains After CHMP Endorses COVID-19-Influenza Combo Shot - Finviz

Mar 02, 2026
pulisher
Mar 02, 2026

Antibiotics Market - GlobeNewswire Inc.

Mar 02, 2026
pulisher
Mar 01, 2026

Sanofi (SNY) and Regeneron's Dupixent Recommended for EU Approval - Finviz

Mar 01, 2026
pulisher
Feb 27, 2026

Kymera Q4 Loss Wider Than Expected, Cash Boost Extends Runway - Finviz

Feb 27, 2026
pulisher
Feb 27, 2026

DNLI Q4 Loss Narrower Than Expected, Hunter Syndrome Drug in Focus - Finviz

Feb 27, 2026
pulisher
Feb 27, 2026

Novavax Stock Gains as Q4 Earnings & Sales Beat Estimates - Finviz

Feb 27, 2026
pulisher
Feb 26, 2026

How Do Investors Really Feel About Sanofi SA? - Sahm

Feb 26, 2026
pulisher
Feb 25, 2026

CYTK Posts a Wider-Than-Expected Q4 Loss, Advances Myqorzo Launch Plans - Finviz

Feb 25, 2026
pulisher
Feb 24, 2026

BMRN Beats on Q4 Earnings, to Withdraw Roctavian From Market - Finviz

Feb 24, 2026
pulisher
Feb 23, 2026

Sanofi's (SNY) R&D Track Record Remains Investor Concern, Says BofA - Finviz

Feb 23, 2026
pulisher
Feb 20, 2026

Manuela Buxo To Become Head of Sanofi's (SNY) Specialty Care Global Business Unit - Finviz

Feb 20, 2026
pulisher
Feb 19, 2026

Teva And Sanofi Duvakitug Data Support IBD Pipeline And Growth Story - Sahm

Feb 19, 2026
pulisher
Feb 17, 2026

Teva and Sanofi’s duvakitug phase 2b maintenance data demonstrated clinically meaningful durable efficacy in ulcerative colitis and Crohn’s disease - Sahm

Feb 17, 2026
pulisher
Feb 16, 2026

RIGL Stock Rises 59% in a Year: Time to Buy, Hold or Sell? - Finviz

Feb 16, 2026
pulisher
Feb 13, 2026

SNY Stock Falls After Board Suddenly Makes Leadership Change - Finviz

Feb 13, 2026
pulisher
Feb 12, 2026

Sanofi Pulls the Emergency Brake: What the Hudson Ouster and Garijo Appointment Really Mean for Investors - CTOL Digital Solutions

Feb 12, 2026
pulisher
Feb 11, 2026

Should Investors Buy, Sell or Hold Amicus Stock Ahead of Q4 Earnings? - Finviz

Feb 11, 2026
pulisher
Feb 10, 2026

SNY's Rare Disease Drug Wins FDA Breakthrough and Japan Orphan Status - Finviz

Feb 10, 2026

Sanofi Adr Azioni (SNY) Dati Finanziari

Reddito

loading

Reddito netto

loading

Flusso di cassa

loading

EPS

loading
PFE PFE
$26.96
price up icon 0.15%
NVO NVO
$37.86
price up icon 0.92%
$138.90
price down icon 0.36%
$349.70
price down icon 0.53%
NVS NVS
$153.88
price down icon 0.11%
MRK MRK
$119.81
price down icon 1.41%
Capitalizzazione:     |  Volume (24 ore):